🔥 Would you like to be featured in our newsletter and get noticed, QUICKLY 🚀? Simply reply to this email or write to editor@digitalhealthbuzz.com, and we can take it from there.
THE 60-SECOND BUZZ!
A blockbuster antibody alliance, an AI receptionist startup growing 10×, and a new cancer-screening blood test. Here’s what actually matters.
💰 Regeneron and Sanofi expand antibody alliance in a potential $8B deal
Sanofi is putting $1 billion upfront on the table, with up to $7 billion more tied to milestones. That scale says something louder than any keynote: antibody pipelines remain one of pharma’s fiercest battlegrounds.
Why it matters: The deal could accelerate multiple programs—but the headline value is contingent, not guaranteed.
🤖 Parakeet Health raises $10M after reporting 10× growth
The startup’s AI agents handle patient conversations and scheduling. Its Series A will fund hiring, product work, and expansion into more specialties.
Reality check: “10× growth” is the company’s reported figure; the durable test is whether providers keep using it after the pilot glow wears off.
🩸 Abbott launches a blood-test option for colorectal cancer screening
SimpleScreen CRC is aimed primarily at eligible patients who do not complete preferred stool-based or visual screening. The intriguing part isn’t replacing colonoscopy—it’s reaching people who might otherwise skip screening entirely.
THE BIG QUESTION
Healthcare’s newest front door may not look like a clinic. It could be an AI voice or a routine blood draw. Which one will patients actually trust?
📣 Follow Digital Health Buzz on X for the fast-moving stories between editions.
PARTNER WITH DIGITAL HEALTH BUZZ
Want to reach a targeted audience of health founders and innovators? Get noticed quickly: editor@digitalhealthbuzz.com
🔥 Keep up with the most interesting health startups, deals, launches, and healthcare shifts.
